Bevacizumab for Central Retinal Vein Occlusion Study

This study has been completed.
Information provided by (Responsible Party):
Anders Kvanta, St. Erik Eye Hospital Identifier:
First received: May 20, 2009
Last updated: November 21, 2011
Last verified: November 2011
Central retinal vein occlusion is a leading cause of severe visual impairment. Until now, no treatment has been available to improve visual acuity. The present study intends to investigate if intravitreal bevacizumab can improve visual acuity as compared to sham-treated control patients.

Condition Intervention Phase
Central Retinal Vein Occlusion
Drug: bevacizumab
Drug: Sham bevacizumab injection
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Prospective, Randomized, Controlled Study on Intravitreal Bevacizumab (Avastin) for Central Retinal Vein Occlusion (CRVO)

Resource links provided by NLM:

Further study details as provided by St. Erik Eye Hospital:

Primary Outcome Measures:
  • The proportion of patients gaining 15 ETDRS letters or more [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change in foveal thickness [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Cases of neovascular glaucoma [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Enrollment: 60
Study Start Date: May 2009
Study Completion Date: September 2011
Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Intravitreal bevacizumab Drug: bevacizumab
Intravitreal injection of 1.25 mg bevacizumab
Sham Comparator: Sham injection Drug: Sham bevacizumab injection
Sham intravitreal injection


Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • CRVO with duration < 6 months
  • Visual acuity of 20/800 to 20/50

Exclusion Criteria:

  • CRVO with duration of > 6 months
  • previous treatment with anti-angiogenic drugs
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00906685

St Eriks Eye Hospital
Stockholm, Sweden, 11282
Sponsors and Collaborators
Anders Kvanta
Principal Investigator: Anders Kvanta, MD, PhD St Eriks Eye Hospital
  More Information

No publications provided

Responsible Party: Anders Kvanta, Professor, St. Erik Eye Hospital Identifier: NCT00906685     History of Changes
Other Study ID Numbers: ACRVO
Study First Received: May 20, 2009
Last Updated: November 21, 2011
Health Authority: Sweden: Medical Products Agency

Keywords provided by St. Erik Eye Hospital:
Macular edema

Additional relevant MeSH terms:
Retinal Vein Occlusion
Cardiovascular Diseases
Embolism and Thrombosis
Eye Diseases
Retinal Diseases
Vascular Diseases
Venous Thrombosis
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses processed this record on November 24, 2015